Does Rallies show Form 4 insider transactions for TLPH?

Yes. Rallies tracks TLPH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TLPH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TLPH. It does not provide personalized investment advice.

TLPH (Talphera, Inc. Common Stock) Stock Analysis - Insider Trades

Talphera, Inc. Common Stock (TLPH) is a publicly traded Healthcare sector company. As of May 21, 2026, TLPH trades at $0.85 with a market cap of $41.38M and a P/E ratio of -2.37. TLPH moved -1.51% today. Year to date, TLPH is -33.01%; over the trailing twelve months it is +59.81%. Its 52-week range spans $0.38 to $1.57. Analyst consensus is strong buy with an average price target of $3.17. Rallies surfaces TLPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TLPH stock inside the company?

Recent TLPH insider activity includes Angotti Vincent J. bought 213.31K, Angotti Vincent J. bought 105.36K, Aslam Shakil bought 35.00K, Dasu Badri N bought 35.00K, and ASADORIAN RAFFI bought 45.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TLPH Key Metrics

Key financial metrics for TLPH
Metric	Value
Price	$0.85
Market Cap	$41.38M
P/E Ratio	-2.37
EPS	$-0.34
Dividend Yield	0.00%
52-Week High	$1.57
52-Week Low	$0.38
Volume	1
Avg Volume	0
Revenue (TTM)	$28.00K
Net Income	$-14.29M
Gross Margin	0.00%

Recent TLPH Insider Trades

Angotti Vincent J. bought 213.31K (~$125.00K) on Mar 13, 2026.
Angotti Vincent J. bought 105.36K (~$85.59K) on Feb 12, 2026.
Aslam Shakil bought 35.00K (~$28.43K) on Feb 12, 2026.
Dasu Badri N bought 35.00K (~$28.43K) on Feb 12, 2026.
ASADORIAN RAFFI bought 45.00K (~$36.55K) on Feb 12, 2026.

Latest TLPH News

Talphera Advances NEFRO Phase 2 Enrollment, Reports 18% Q1 R&D Spend Rise — May 14, 2026
Talphera Reports Q1 Cash of $21.1M and 50% NEPHRO CRRT Enrollment — May 13, 2026
Talphera Hits 50% Enrollment in NEPHRO-CRRT Trial After 60% Patient Cut — Mar 2, 2026

TLPH Analyst Consensus

3 analysts cover TLPH: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $3.17.

Common questions about TLPH

Who is trading TLPH stock inside the company?: Recent TLPH insider activity includes Angotti Vincent J. bought 213.31K, Angotti Vincent J. bought 105.36K, Aslam Shakil bought 35.00K, Dasu Badri N bought 35.00K, and ASADORIAN RAFFI bought 45.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TLPH?: Yes. Rallies tracks TLPH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TLPH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TLPH. It does not provide personalized investment advice.